Inhibition of LRRK2 kinase activity stimulates macroautophagy

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 12, 2013, Pages 2900-2910

  Manzoni, Claudia ^a   Mamais, Adamantios ^a,b   Dihanich, Sybille ^a   Abeti, Rosella ^a   Soutar, Marc P M ^a   Plun Favreau, Helene ^a   Giunti, Paola ^a   Tooze, Sharon A ^c   Bandopadhyay, Rina ^a,b   Lewis, Patrick A ^a,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF READING   (United Kingdom)

Author keywords

COR; DMSO; DPBS; EDTA; LC3; LRRK2; Macroautophagy; MTOR; P62; Parkinson's disease; ROC; SDS; WIPI2

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN P62;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; MACROAUTOPHAGY; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SIGNAL TRANSDUCTION;

EID: 84882754673     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.07.020     Document Type: Article

References (53)

1. Lewis P.A. The function of ROCO proteins in health and disease. Biol. Cell 2009, 101:183-191.
2. Cookson M.R. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease, Nature reviews. Neuroscience 2010, 11:791-797.
3. Nalls M.A., Plagnol V., Hernandez D.G., Sharma M., Sheerin U.M., Saad M., Simon-Sanchez J., Schulte C., Lesage S., Sveinbjornsdottir S., Stefansson K., Martinez M., Hardy J., Heutink P., Brice A., Gasser T., Singleton A.B., Wood N.W. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649.
4. Ross O.A., Soto-Ortolaza A.I., Heckman M.G., Aasly J.O., Abahuni N., Annesi G., Bacon J.A., Bardien S., Bozi M., Brice A., Brighina L., Van Broeckhoven C., Carr J., Chartier-Harlin M.C., Dardiotis E., Dickson D.W., Diehl N.N., Elbaz A., Ferrarese C., Ferraris A., Fiske B., Gibson J.M., Gibson R., Hadjigeorgiou G.M., Hattori N., Ioannidis J.P., Jasinska-Myga B., Jeon B.S., Kim Y.J., Klein C., Kruger R., Kyratzi E., Lesage S., Lin C.H., Lynch T., Maraganore D.M., Mellick G.D., Mutez E., Nilsson C., Opala G., Park S.S., Puschmann A., Quattrone A., Sharma M., Silburn P.A., Sohn Y.H., Stefanis L., Tadic V., Theuns J., Tomiyama H., Uitti R.J., Valente E.M., van de Loo S., Vassilatis D.K., Vilarino-Guell C., White L.R., Wirdefeldt K., Wszolek Z.K., Wu R.M., Farrer M.J. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 2011, 10:898-908.
5. Greggio E., Cookson M.R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009, 1. (pii: e00002).
6. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16842-16847.
7. Lewis P.A., Greggio E., Beilina A., Jain S., Baker A., Cookson M.R. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun. 2007, 357:668-671.
8. Li X., Tan Y.C., Poulose S., Olanow C.W., Huang X.Y., Yue Z. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem. 2007, 103:238-247.
9. Daniels V., Vancraenenbroeck R., Law B.M., Greggio E., Lobbestael E., Gao F., De Maeyer M., Cookson M.R., Harvey K., Baekelandt V., Taymans J.M. Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J. Neurochem. 2011, 116:304-315.
10. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., van der Brug M.P., Beilina A., Blackinton J., Thomas K.J., Ahmad R., Miller D.W., Kesavapany S., Singleton A., Lees A., Harvey R.J., Harvey K., Cookson M.R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 2006, 23:329-341.
11. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 2006, 9:1231-1233.
12. Lee B.D., Shin J.H., VanKampen J., Petrucelli L., West A.B., Ko H.S., Lee Y.I., Maguire-Zeiss K.A., Bowers W.J., Federoff H.J., Dawson V.L., Dawson T.M. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat. Med. 2010, 16:998-1000.
13. Plowey E.D., Cherra S.J., Liu Y.J., Chu C.T. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem. 2008, 105:1048-1056.
14. Alegre-Abarrategui J., Christian H., Lufino M.M., Mutihac R., Venda L.L., Ansorge O., Wade-Martins R. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009, 18:4022-4034.
15. Tong Y., Yamaguchi H., Giaime E., Boyle S., Kopan R., Kelleher R.J., Shen J. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:9879-9884.
16. Ramonet D., Daher J.P., Lin B.M., Stafa K., Kim J., Banerjee R., Westerlund M., Pletnikova O., Glauser L., Yang L., Liu Y., Swing D.A., Beal M.F., Troncoso J.C., McCaffery J.M., Jenkins N.A., Copeland N.G., Galter D., Thomas B., Lee M.K., Dawson T.M., Dawson V.L., Moore D.J. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 2011, 6:e18568.
17. Gomez-Suaga P., Luzon-Toro B., Churamani D., Zhang L., Bloor-Young D., Patel S., Woodman P.G., Churchill G.C., Hilfiker S. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum. Mol. Genet. 2012, 21:511-525.
18. Xiong Y., Coombes C.E., Kilaru A., Li X., Gitler A.D., Bowers W.J., Dawson V.L., Dawson T.M., Moore D.J. GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet. 2010, 6:e1000902.
19. Sanchez-Danes A., Richaud-Patin Y., Carballo-Carbajal I., Jimenez-Delgado S., Caig C., Mora S., Di Guglielmo C., Ezquerra M., Patel B., Giralt A., Canals J.M., Memo M., Alberch J., Lopez-Barneo J., Vila M., Cuervo A.M., Tolosa E., Consiglio A., Raya A. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol. Med. 2012, 4:380-395.
20. Bravo-San Pedro J.M., Niso-Santano M., Gomez-Sanchez R., Pizarro-Estrella E., Aiastui-Pujana A., Gorostidi A., Climent V., Lopez de Maturana R., Sanchez-Pernaute R., Lopez de Munain A., Fuentes J.M., Gonzalez-Polo R.A. The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. Cell. Mol. Life Sci. 2013, 70:121-136.
21. Tong Y., Giaime E., Yamaguchi H., Ichimura T., Liu Y., Si H., Cai H., Bonventre J.V., Shen J. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol. Neurodegener. 2012, 7:2.
22. Imai Y., Gehrke S., Wang H.Q., Takahashi R., Hasegawa K., Oota E., Lu B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 2008, 27:2432-2443.
23. Kumar A., Greggio E., Beilina A., Kaganovich A., Chan D., Taymans J.M., Wolozin B., Cookson M.R. The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One 2010, 5:e8730.
24. Barrett J.C., Hansoul S., Nicolae D.L., Cho J.H., Duerr R.H., Rioux J.D., Brant S.R., Silverberg M.S., Taylor K.D., Barmada M.M., Bitton A., Dassopoulos T., Datta L.W., Green T., Griffiths A.M., Kistner E.O., Murtha M.T., Regueiro M.D., Rotter J.I., Schumm L.P., Steinhart A.H., Targan S.R., Xavier R.J., Libioulle C., Sandor C., Lathrop M., Belaiche J., Dewit O., Gut I., Heath S., Laukens D., Mni M., Rutgeerts P., Van Gossum A., Zelenika D., Franchimont D., Hugot J.P., de Vos M., Vermeire S., Louis E., Cardon L.R., Anderson C.A., Drummond H., Nimmo E., Ahmad T., Prescott N.J., Onnie C.M., Fisher S.A., Marchini J., Ghori J., Bumpstead S., Gwilliam R., Tremelling M., Deloukas P., Mansfield J., Jewell D., Satsangi J., Mathew C.G., Parkes M., Georges M., Daly M.J. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 2008, 40:955-962.
25. Bandmann O., Cookson M.R. Parkinson disease, cancer, and LRRK2: causation or association?. Neurology 2012, 78:772-773.
26. Zhang F.R., Huang W., Chen S.M., Sun L.D., Liu H., Li Y., Cui Y., Yan X.X., Yang H.T., Yang R.D., Chu T.S., Zhang C., Zhang L., Han J.W., Yu G.Q., Quan C., Yu Y.X., Zhang Z., Shi B.Q., Zhang L.H., Cheng H., Wang C.Y., Lin Y., Zheng H.F., Fu X.A., Zuo X.B., Wang Q., Long H., Sun Y.P., Cheng Y.L., Tian H.Q., Zhou F.S., Liu H.X., Lu W.S., He S.M., Du W.L., Shen M., Jin Q.Y., Wang Y., Low H.Q., Erwin T., Yang N.H., Li J.Y., Zhao X., Jiao Y.L., Mao L.G., Yin G., Jiang Z.X., Wang X.D., Yu J.P., Hu Z.H., Gong C.H., Liu Y.Q., Liu R.Y., Wang D.M., Wei D., Liu J.X., Cao W.K., Cao H.Z., Li Y.P., Yan W.G., Wei S.Y., Wang K.J., Hibberd M.L., Yang S., Zhang X.J., Liu J.J. Genomewide association study of leprosy. N. Engl. J. Med. 2009, 361:2609-2618.
27. Ramsden N., Perrin J., Ren Z., Lee B.D., Zinn N., Dawson V.L., Tam D., Bova M., Lang M., Drewes G., Bantscheff M., Bard F., Dawson T.M., Hopf C. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem. Biol. 2011, 6:1021-1028.
28. Deng X., Dzamko N., Prescott A., Davies P., Liu Q., Yang Q., Lee J.D., Patricelli M.P., Nomanbhoy T.K., Alessi D.R., Gray N.S. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol. 2011, 7:203-205.
29. Repetto G., del Peso A., Zurita J.L. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat. Protoc. 2008, 3:1125-1131.
30. Milton R.H., Abeti R., Averaimo S., DeBiasi S., Vitellaro L., Jiang L., Curmi P.M., Breit S.N., Duchen M.R., Mazzanti M. CLIC1 function is required for beta-amyloid-induced generation of reactive oxygen species by microglia. J. Neurosci. Off. J. Soc. Neurosci. 2008, 28:11488-11499.
31. Moehle M.S., Webber P.J., Tse T., Sukar N., Standaert D.G., DeSilva T.M., Cowell R.M., West A.B. LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci. Off. J. Soc. Neurosci. 2012, 32:1602-1611.
32. Kim B., Yang M.S., Choi D., Kim J.H., Kim H.S., Seol W., Choi S., Jou I., Kim E.Y., Joe E.H. Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One 2012, 7:e34693.
33. Gardet A., Benita Y., Li C., Sands B.E., Ballester I., Stevens C., Korzenik J.R., Rioux J.D., Daly M.J., Xavier R.J., Podolsky D.K. LRRK2 is involved in the IFN-gamma response and host response to pathogens. J. Immunol. 2010, 185:5577-5585.
34. Hakimi M., Selvanantham T., Swinton E., Padmore R.F., Tong Y., Kabbach G., Venderova K., Girardin S.E., Bulman D.E., Scherzer C.R., Lavoie M.J., Gris D., Park D.S., Angel J.B., Shen J., Philpott D.J., Schlossmacher M.G. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J. Neural Transm. 2011, 118:795-808.
35. Geng J., Klionsky D.J. The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep. 2008, 9:859-864.
36. Reith A.D., Bamborough P., Jandu K., Andreotti D., Mensah L., Dossang P., Choi H.G., Deng X., Zhang J., Alessi D.R., Gray N.S. GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. Bioorg. Med. Chem. Lett. 2012, 22:5625-5629.
37. Trancikova A., Mamais A., Webber P.J., Stafa K., Tsika E., Glauser L., West A.B., Bandopadhyay R., Moore D.J. Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations. PLoS One 2012, 7:e47784.
38. Polson H.E., de Lartigue J., Rigden D.J., Reedijk M., Urbe S., Clague M.J., Tooze S.A. Mammalian Atg18 (WIPI2) localizes to omegasome-anchored phagophores and positively regulates LC3 lipidation. Autophagy 2010, 6:506-522.
39. Itakura E., Mizushima N. p62 Targeting to the autophagosome formation site requires self-oligomerization but not LC3 binding. J. Cell Biol. 2011, 192:17-27.
40. Krex D., Mohr B., Hauses M., Ehninger G., Schackert H.K., Schackert G. Identification of uncommon chromosomal aberrations in the neuroglioma cell line H4 by spectral karyotyping. J. Neurooncol. 2001, 52:119-128.
41. Arnstein P., Taylor D.O., Nelson-Rees W.A., Huebner R.J., Lennette E.H. Propagation of human tumors in antithymocyte serum-treated mice. J. Natl. Cancer Inst. 1974, 52:71-84.
42. He C., Klionsky D.J. Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 2009, 43:67-93.
43. Webber P.J., Smith A.D., Sen S., Renfrow M.B., Mobley J.A., West A.B. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J. Mol. Biol. 2011, 412:94-110.
44. Taymans J.M., Vancraenenbroeck R., Ollikainen P., Beilina A., Lobbestael E., De Maeyer M., Baekelandt V., Cookson M.R. LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS One 2011, 6:e23207.
45. Gasper R., Meyer S., Gotthardt K., Sirajuddin M., Wittinghofer A. It takes two to tango: regulation of G proteins by dimerization. Nat. Rev. Mol. Cell Biol. 2009, 10:423-429.
46. Lewis P.A., Manzoni C. LRRK2 and human disease: a complicated question or a question of complexes?. Sci. Signal. 2012, 5:pe2.
47. Rudenko I.N., Chia R., Cookson M.R. Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?. BMC Med. 2012, 10:20.
48. Greggio E. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease. Biochem. Soc. Trans. 2012, 40:1058-1062.
49. Cheong H., Lu C., Lindsten T., Thompson C.B. Therapeutic targets in cancer cell metabolism and autophagy. Nat. Biotechnol. 2012, 30:671-678.
50. Menzies F.M., Moreau K., Rubinsztein D.C. Protein misfolding disorders and macroautophagy. Curr. Opin. Cell Biol. 2011, 23:190-197.
51. Brain O., Cooney R., Simmons A., Jewell D. Functional consequences of mutations in the autophagy genes in the pathogenesis of Crohn's disease. Inflamm. Bowel Dis. 2012, 18:778-781.
52. Cardoso C.C., Pereira A.C., de Sales Marques C., Moraes M.O. Leprosy susceptibility: genetic variations regulate innate and adaptive immunity, and disease outcome. Future Microbiol. 2011, 6:533-549.
53. Manzoni C. LRRK2 and autophagy: a common pathway for disease. Biochem. Soc. Trans. 2012, 40:1147-1151.